

1 HOUSE BILL 260

2 **53RD LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2017**

3 INTRODUCED BY

4 Deborah A. Armstrong

5
6
7
8
9
10 AN ACT

11 RELATING TO HEALTH; AMENDING THE NEW MEXICO DRUG, DEVICE AND
12 COSMETIC ACT TO PROVIDE FOR REGULATION OF BIOSIMILAR PRODUCTS.

13
14 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

15 SECTION 1. Section 26-1-2 NMSA 1978 (being Laws 1967,
16 Chapter 23, Section 2, as amended) is amended to read:

17 "26-1-2. DEFINITIONS.--As used in the New Mexico Drug,
18 Device and Cosmetic Act:

19 A. "board" means the board of pharmacy or its duly
20 authorized agent;

21 B. "person" includes an individual, partnership,
22 corporation, association, institution or establishment;

23 C. "biological product" means a virus, therapeutic
24 serum, toxin, antitoxin, protein or analogous product

25 applicable to the prevention, treatment or cure of diseases or

.205966.1

underscored material = new
[bracketed material] = delete

underscored material = new
[bracketed material] = delete

1 injuries of humans and domestic animals, and, as used within
2 the meaning of this definition:

3 (1) a "virus" is interpreted to be a product
4 containing the minute living cause of an infectious disease and
5 includes filterable viruses, bacteria, rickettsia, fungi and
6 protozoa;

7 (2) a "therapeutic serum" is a product
8 obtained from blood by removing the clot or clot components and
9 the blood cells;

10 (3) a "toxin" is a product containing a
11 soluble substance poisonous to laboratory animals or humans in
12 doses of one milliliter or less of the product and, following
13 the injection of nonfatal doses into an animal, having the
14 property of or causing to be produced therein another soluble
15 substance that specifically neutralizes the poisonous substance
16 and that is demonstrable in the serum of the animal thus
17 immunized; ~~and~~

18 (4) an "antitoxin" is a product containing the
19 soluble substance in serum or other body fluid of an immunized
20 animal that specifically neutralizes the toxin against which
21 the animal is immune; and

22 (5) a "protein" excludes any chemically
23 synthesized polypeptide;

24 D. "controlled substance" means a drug, substance
25 or immediate precursor enumerated in Schedules I through V of

.205966.1

underscoring material = new
~~[bracketed material] = delete~~

1 the Controlled Substances Act;

2 E. "drug" means articles:

3 (1) recognized in an official compendium;

4 (2) intended for use in the diagnosis, cure,
5 mitigation, treatment or prevention of disease in humans or
6 other animals and includes the domestic animal biological
7 products regulated under the federal Virus-Serum-Toxin Act, 37
8 Stat 832-833, 21 U.S.C. 151-158, and the biological products
9 applicable to humans regulated under Federal 58 Stat 690, as
10 amended, 42 U.S.C. 216, Section 351, 58 Stat 702, as amended,
11 and 42 U.S.C. 262;

12 (3) other than food, that affect the structure
13 or any function of the human body or the bodies of other
14 animals; and

15 (4) intended for use as a component of
16 Paragraph (1), (2) or (3) of this subsection, but "drug" does
17 not include devices or their component parts or accessories;

18 F. "dangerous drug" means a drug, other than a
19 controlled substance enumerated in Schedule I of the Controlled
20 Substances Act, that because of a potentiality for harmful
21 effect or the method of its use or the collateral measures
22 necessary to its use is not safe except under the supervision
23 of a practitioner licensed by law to direct the use of such
24 drug and hence for which adequate directions for use cannot be
25 prepared. "Adequate directions for use" means directions under

.205966.1

underscoring material = new
~~[bracketed material] = delete~~

1 which the layperson can use a drug or device safely and for the
2 purposes for which it is intended. A drug shall be dispensed
3 only upon the prescription or drug order of a practitioner
4 licensed by law to administer or prescribe the drug if it:

5 (1) is a habit-forming drug and contains any
6 quantity of a narcotic or hypnotic substance or a chemical
7 derivative of such substance that has been found under the
8 federal act and the board to be habit forming;

9 (2) because of its toxicity or other potential
10 for harmful effect or the method of its use or the collateral
11 measures necessary to its use is not safe for use except under
12 the supervision of a practitioner licensed by law to administer
13 or prescribe the drug;

14 (3) is limited by an approved application by
15 Section 505 of the federal act to the use under the
16 professional supervision of a practitioner licensed by law to
17 administer or prescribe the drug;

18 (4) bears the legend: "Caution: federal law
19 prohibits dispensing without prescription.";

20 (5) bears the legend: "Caution: federal law
21 restricts this drug to use by or on the order of a licensed
22 veterinarian."; or

23 (6) bears the legend "RX only";

24 G. "counterfeit drug" means a drug that is
25 deliberately and fraudulently mislabeled with respect to its

.205966.1

underscored material = new
~~[bracketed material] = delete~~

1 identity, ingredients or sources. Types of such pharmaceutical
2 counterfeits may include:

3 (1) "identical copies", which are counterfeits
4 made with the same ingredients, formulas and packaging as the
5 originals but not made by the original manufacturer;

6 (2) "look-alikes", which are products that
7 feature high-quality packaging and convincing appearances but
8 contain little or no active ingredients and may contain harmful
9 substances;

10 (3) "rejects", which are drugs that have been
11 rejected by the manufacturer for not meeting quality standards;
12 and

13 (4) "relabels", which are drugs that have
14 passed their expiration dates or have been distributed by
15 unauthorized foreign sources and may include placebos created
16 for late-phase clinical trials;

17 H. "device", except when used in Subsection [P] Q
18 of this section and in Subsection G of Section 26-1-3,
19 Subsection L and Paragraph (4) of Subsection A of Section
20 26-1-11 and Subsection C of Section 26-1-24 NMSA 1978, means an
21 instrument, apparatus, implement, machine, contrivance,
22 implant, in vitro reagent or other similar or related article,
23 including any component, part or accessory, that is:

24 (1) recognized in an official compendium;

25 (2) intended for use in the diagnosis of

.205966.1

underscoring material = new
~~[bracketed material] = delete~~

1 disease or other conditions or in the cure, mitigation,
2 treatment or prevention of disease in humans or other animals;
3 or

4 (3) intended to affect the structure or a
5 function of the human body or the bodies of other animals and
6 that does not achieve any of its principal intended purposes
7 through chemical action within or on the human body or the
8 bodies of other animals and that is not dependent on being
9 metabolized for achievement of any of its principal intended
10 purposes;

11 I. "prescription" means an order given individually
12 for the person for whom prescribed, either directly from a
13 licensed practitioner or the practitioner's agent to the
14 pharmacist, including by means of electronic transmission, or
15 indirectly by means of a written order signed by the
16 prescriber, and bearing the name and address of the prescriber,
17 the prescriber's license classification, the name and address
18 of the patient, the name and quantity of the drug prescribed,
19 directions for use and the date of issue;

20 J. "practitioner" means a certified advanced
21 practice chiropractic physician, physician, doctor of oriental
22 medicine, dentist, veterinarian, euthanasia technician,
23 certified nurse practitioner, clinical nurse specialist,
24 pharmacist, pharmacist clinician, certified nurse-midwife,
25 physician assistant, prescribing psychologist, dental

.205966.1

underscored material = new
[bracketed material] = delete

1 hygienist, optometrist or other person licensed or certified to
2 prescribe and administer drugs that are subject to the New
3 Mexico Drug, Device and Cosmetic Act;

4 K. "cosmetic" means:

5 (1) articles intended to be rubbed, poured,
6 sprinkled or sprayed on, introduced into or otherwise applied
7 to the human body or any part thereof for cleansing,
8 beautifying, promoting attractiveness or altering the
9 appearance; and

10 (2) articles intended for use as a component
11 of any articles enumerated in Paragraph (1) of this subsection,
12 except that the term shall not include soap;

13 L. "interchangeable biological product" means a
14 biological product that:

15 (1) the federal food and drug administration
16 has licensed and determined to meet the federal standards for
17 "interchangeable" or "interchangeability"; or

18 (2) the federal food and drug administration
19 has determined to be a therapeutic equivalent as set forth in
20 the latest edition of or supplement to the federal food and
21 drug administration's approved drug products with therapeutic
22 equivalence evaluations, also known as the "orange book";

23 [~~E.~~] M. "official compendium" means the official
24 United States pharmacopoeia national formulary or the official
25 homeopathic pharmacopoeia of the United States or any

.205966.1

underscoring material = new
~~[bracketed material] = delete~~

1 supplement to either of them;

2 ~~[M-]~~ N. "label" means a display of written, printed
3 or graphic matter upon the immediate container of an article.

4 A requirement made by or under the authority of the New Mexico
5 Drug, Device and Cosmetic Act that any word, statement or other
6 information appear on the label shall not be considered to be
7 complied with unless the word, statement or other information
8 also appears on the outside container or wrapper, if any, of
9 the retail package of the article or is easily legible through
10 the outside container or wrapper;

11 ~~[N-]~~ O. "immediate container" does not include
12 package liners;

13 ~~[O-]~~ P. "labeling" means all labels and other
14 written, printed or graphic matter:

15 (1) on an article or its containers or
16 wrappers; or

17 (2) accompanying an article;

18 ~~[P-]~~ Q. "misbranded" means a label to an article
19 that is misleading. In determining whether the label is
20 misleading, there shall be taken into account, among other
21 things, not only representations made or suggested by
22 statement, word, design, device or any combination of the
23 foregoing, but also the extent to which the label fails to
24 reveal facts material in the light of such representations or
25 material with respect to consequences that may result from the

.205966.1

underscoring material = new
~~[bracketed material] = delete~~

1 use of the article to which the label relates under the
2 conditions of use prescribed in the label or under such
3 conditions of use as are customary or usual;

4 ~~[Q-]~~ R. "advertisement" means all representations
5 disseminated in any manner or by any means, other than by
6 labeling, for the purpose of inducing, or that are likely to
7 induce, directly or indirectly, the purchase of drugs, devices
8 or cosmetics;

9 ~~[R-]~~ S. "antiseptic", when used in the labeling or
10 advertisement of an antiseptic, shall be considered to be a
11 representation that it is a germicide, except in the case of a
12 drug purporting to be or represented as an antiseptic for
13 inhibitory use as a wet dressing, ointment, dusting powder or
14 such other use as involves prolonged contact with the body;

15 ~~[S-]~~ T. "new drug" means a drug:

16 (1) the composition of which is such that the
17 drug is not generally recognized, among experts qualified by
18 scientific training and experience to evaluate the safety and
19 efficacy of drugs, as safe and effective for use under the
20 conditions prescribed, recommended or suggested in the labeling
21 thereof; or

22 (2) the composition of which is such that the
23 drug, as a result of investigation to determine its safety and
24 efficacy for use under such conditions, has become so
25 recognized, but that has not, otherwise than in such

.205966.1

underscored material = new
[bracketed material] = delete

1 investigations, been used to a material extent or for a
2 material time under such conditions;

3 ~~[F.]~~ U. "contaminated with filth" applies to a
4 drug, device or cosmetic not securely protected from dirt, dust
5 and, as far as may be necessary by all reasonable means, from
6 all foreign or injurious contaminations, or a drug, device or
7 cosmetic found to contain dirt, dust, foreign or injurious
8 contamination or infestation;

9 ~~[H.]~~ V. "selling of drugs, devices or cosmetics"
10 shall be considered to include the manufacture, production,
11 processing, packing, exposure, offer, possession and holding of
12 any such article for sale and the sale and the supplying or
13 applying of any such article in the conduct of a drug or
14 cosmetic establishment;

15 ~~[V.]~~ W. "color additive" means a material that:

16 (1) is a dye, pigment or other substance made
17 by a process of synthesis or similar artifice or extracted,
18 isolated or otherwise derived, with or without intermediate or
19 final change of identity, from a vegetable, mineral, animal or
20 other source; or

21 (2) when added or applied to a drug or
22 cosmetic or to the human body or a part thereof, is capable,
23 alone or through reaction with other substances, of imparting
24 color thereto; except that such term does not include any
25 material that has been or hereafter is exempted under the

.205966.1

underscored material = new
[bracketed material] = delete

1 federal act;

2 [W.] X. "federal act" means the Federal Food, Drug,
3 and Cosmetic Act;

4 [~~X.~~] Y. "restricted device" means a device for
5 which the sale, distribution or use is lawful only upon the
6 written or oral authorization of a practitioner licensed by law
7 to administer, prescribe or use the device and for which the
8 federal food and drug administration requires special training
9 or skills of the practitioner to use or prescribe. This
10 definition does not include custom devices defined in the
11 federal act and exempt from performance standards or premarket
12 approval requirements under Section 520(b) of the federal act;

13 [~~Y.~~] Z. "prescription device" means a device that,
14 because of its potential for harm, the method of its use or the
15 collateral measures necessary to its use, is not safe except
16 under the supervision of a practitioner licensed in this state
17 to direct the use of such device and for which "adequate
18 directions for use" cannot be prepared, but that bears the
19 label: "Caution: federal law restricts this device to sale by
20 or on the order of a _____", the blank to be filled with
21 the word "physician", "physician assistant", "certified
22 advanced practice chiropractic physician", "doctor of oriental
23 medicine", "dentist", "veterinarian", "euthanasia technician",
24 "certified nurse practitioner", "clinical nurse specialist",
25 "pharmacist", "pharmacist clinician", "certified nurse-

.205966.1

underscored material = new
[bracketed material] = delete

1 midwife", [~~or~~] "dental hygienist" or "optometrist" or with the
2 descriptive designation of any other practitioner licensed in
3 this state to use or order the use of the device;

4 [~~Z.~~] AA. "valid practitioner-patient relationship"
5 means a professional relationship, as defined by the
6 practitioner's licensing board, between the practitioner and
7 the patient;

8 [~~AA.~~] BB. "pedigree" means the recorded history of
9 a drug; and

10 [~~BB.~~] CC. "drug order" means an order either
11 directly from a licensed practitioner or the practitioner's
12 agent to the pharmacist, including by means of electronic
13 transmission or indirectly by means of a written order signed
14 by the licensed practitioner or the practitioner's agent, and
15 bearing the name and address of the practitioner and the
16 practitioner's license classification and the name and quantity
17 of the drug or device ordered for use at an inpatient or
18 outpatient facility."

19 **SECTION 2.** Section 26-3-3 NMSA 1978 (being Laws 1976,
20 Chapter 60, Section 4, as amended) is amended to read:

21 "26-3-3. DRUG AND BIOLOGICAL PRODUCT SELECTION
22 PERMITTED--CONDITIONS--EXCEPTION FOR PROHIBITION--LABELING.--

23 A. Upon receipt of a prescription written by a
24 licensed practitioner who may prescribe drugs or biological
25 products for a drug or biological product for which one or more

.205966.1

underscored material = new
[bracketed material] = delete

1 multiple-source drugs or interchangeable biological products
2 are recognized, listed as final determinations and published in
3 the federal register by the federal department of health and
4 human services, a pharmacist may dispense any one of the drugs
5 or interchangeable biological products that satisfies the final
6 determinations so recognized and listed by the federal
7 department of health and human services and is sold at a lower
8 cost than the drug or biological product listed in the
9 prescription.

10 B. Upon receipt of a prescription written by a
11 licensed practitioner for a drug or biological product that
12 appears on the federal food and drug administration's approved
13 prescription drug products with therapeutic equivalence
14 evaluation list as supplemented, or for a biological product
15 that is listed as interchangeable on the list of the federal
16 food and drug administration's lists of licensed biological
17 products with reference product exclusivity and biosimilar or
18 interchangeable evaluations, as supplemented, a pharmacist may
19 dispense any of the listed therapeutically equivalent drugs or
20 interchangeable biological products that ~~[appears on that list~~
21 ~~and which]~~ is lower in cost than the prescribed drug ~~[listed in~~
22 ~~the prescription]~~ or biological product.

23 C. Drug and biological product selection shall be
24 permitted only under circumstances and conditions set forth in
25 Subsections A and B of this section unless:

.205966.1

underscored material = new
[bracketed material] = delete

1 (1) the licensed practitioner prescribing
2 prohibits drug product or biological product selection. A
3 licensed practitioner shall prohibit drug or biological product
4 selection by [~~writing with his hand~~] handwriting the words "no
5 substitution" or the diminution "no sub" on the face of a
6 prescription; or

7 (2) in the case of a biological product, the
8 person, or representative of the person, for whom the
9 biological product is prescribed requests the prescribed
10 biological product.

11 D. If drug or biological product selection occurs
12 as permitted in Subsections A and B of this section, the
13 pharmacist shall indicate on the label of the dispensed
14 container the brand of drug or the specific biological product
15 prescribed and the name of the drug or interchangeable
16 biological product dispensed.

17 E. A pharmacist who selects an interchangeable
18 biological product shall, prior to dispensing an
19 interchangeable biological product, inform the patient or the
20 patient's representative that:

21 (1) an interchangeable biological product will
22 be substituted for the biological product prescribed; and

23 (2) the patient, or the patient's
24 representative, has the right to refuse the substitution and
25 request that the prescribed biological product be dispensed.

.205966.1

underscored material = new
[bracketed material] = delete

1 ~~[E.]~~ F. A pharmacist may not select a
2 therapeutically equivalent drug or interchangeable biological
3 product unless ~~[he]~~ the pharmacist passes on to the patient all
4 savings between the net cost of the product prescribed and the
5 product dispensed.

6 ~~[F. For purposes of this section, "multiple-source~~
7 ~~drug" means a drug marketed or sold by two or more~~
8 ~~manufacturers, formulators or labelers.]~~

9 G. Within five business days following the
10 dispensing of a biological product, the dispensing pharmacist
11 or the pharmacist's designee shall make an entry of the
12 specific product provided to the patient, including the name of
13 the product and the manufacturer. The communication shall be
14 conveyed by making an entry that is electronically accessible
15 to the prescriber through:

- 16 (1) an interoperable electronic medical
- 17 records system;
- 18 (2) an electronic prescribing technology;
- 19 (3) a pharmacy benefit management system; or
- 20 (4) a pharmacy record.

21 H. Entry into an electronic records system pursuant
22 to Subsection G of this section is presumed to provide notice
23 to the prescriber. Otherwise, the pharmacist shall communicate
24 the biological product dispensed to the prescriber using
25 facsimile, telephone, electronic transmission or other

underscoring material = new
[bracketed material] = delete

1 prevailing means; provided that communication shall not be
2 required when:

3 (1) there is no interchangeable biological
4 product that has been approved by the federal food and drug
5 administration for the product prescribed; or

6 (2) a refill prescription is not changed from
7 the product dispensed on the prior filling of the prescription.

8 I. The board shall maintain a link on its website
9 to the current list of all biological products that the federal
10 food and drug administration has determined to be
11 interchangeable biological products.

12 ~~[G.]~~ J. For purposes of this section:

13 (1) "multiple-source drug" means a drug
14 marketed or sold by two or more manufacturers, formulators or
15 labelers; and

16 (2) "therapeutically equivalent" means drug
17 products ~~[which]~~ that have the same amount of the active drug
18 in the same dosage form ~~[which]~~ that when administered can be
19 expected to provide the same therapeutic effect."